{"id":43559,"date":"2026-02-14T17:26:09","date_gmt":"2026-02-14T17:26:09","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/urothelial-cancer-drugs-market-mordor\/"},"modified":"2026-09-25T01:59:42","modified_gmt":"2026-09-24T16:59:42","slug":"urothelial-cancer-drugs-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/urothelial-cancer-drugs-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uc694\ub85c\uc0c1\ud53c\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/urothelial-cancer-drugs-market_1672379010253_Competitive_Landscape.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/urothelial-cancer-drugs-market-size-image-1770828234494.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud604\ud669<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uc99d\uac00\ud558\ub294 \uc694\ub85c\uc0c1\ud53c\uc554 \ubc1c\ubcd1\ub960<\/li>\n<li class=\"toc-level-3\">4.2.2 1\ucc28 \ud45c\uc900 \uce58\ub8cc\ubc95\uc73c\ub85c \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \ucc44\ud0dd \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.3 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778<\/li>\n<li class=\"toc-level-3\">4.2.4 \ub300\ud615 \uc81c\uc57d\uc0ac \ud30c\ud2b8\ub108\uc2ed\uc744 \ud1b5\ud55c FGFR \uc5b5\uc81c\uc81c \ucd9c\uc2dc \uac00\uc18d\ud654<\/li>\n<li class=\"toc-level-3\">4.2.5 AI \uae30\ubc18 \uc18c\ubcc0 \ubc14\uc774\uc624\ub9c8\ucee4 \uc9c4\ub2e8\uc73c\ub85c \uce58\ub8cc \uac00\ub2a5 \ud658\uc790\uad70 \ud655\ub300<\/li>\n<li class=\"toc-level-3\">4.2.6 ADC + \uba74\uc5ed\ud56d\uc554\uc81c(IO) \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \uba54\ub514\ucf00\uc5b4 \ubc0f \ubbfc\uac04 \ubcf4\ud5d8\uc0ac\uc758 \uc0c1\ud658 \ud655\ub300<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.3.1 \uba74\uc5ed \uc694\ubc95 \ubc0f ADC\uc758 \ub192\uc740 \ube44\uc6a9<\/li>\n<li class=\"toc-level-3\">4.3.2 \uba74\uc5ed \uad00\ub828 \ubd80\uc791\uc6a9\uc73c\ub85c \uc778\ud55c \uc7a5\uae30 \ubcf5\uc6a9 \uc900\uc218\uc728 \uc800\ud558<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc804 \uc138\uacc4\uc801\uc778 BCG \uc81c\uc870 \ubd80\uc871\uc73c\ub85c NMIBC \uce58\ub8cc \uc694\ubc95 \uc7a5\uae30\ud654<\/li>\n<li class=\"toc-level-3\">4.3.4 \uc2e0\ud765 \uc2dc\uc7a5\uc5d0\uc11c \ub3d9\ubc18 \uc9c4\ub2e8 \ud14c\uc2a4\ud2b8 \uc811\uadfc\uc131 \uc81c\ud55c<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.4.1 \uad6c\ub9e4\uc790\/\uc18c\ube44\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.4.2 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.4.3 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.4.4 \ub300\uccb4 \uc81c\ud488\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.4.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc \ub4f1\uae09\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 \ud654\ud559\uc694\ubc95<\/li>\n<li class=\"toc-level-4\">5.1.1.1 \ubc31\uae08 \uae30\ubc18<\/li>\n<li class=\"toc-level-4\">5.1.1.2 \ube44\ubc31\uae08<\/li>\n<li class=\"toc-level-3\">5.1.2 \uba74\uc5ed\uc694\ubc95<\/li>\n<li class=\"toc-level-4\">5.1.2.1 PD-1 \/ PD-L1 \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-4\">5.1.2.2 CTLA-4 \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-4\">5.1.2.3 \uc885\uc591 \uc6a9\ud574 \ubc14\uc774\ub7ec\uc2a4 \ubc0f \ubc31\uc2e0<\/li>\n<li class=\"toc-level-3\">5.1.3 \ud45c\uc801 \uce58\ub8cc<\/li>\n<li class=\"toc-level-4\">5.1.3.1 FGFR \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-4\">5.1.3.2 HER2 \/ \ub125\ud2f4-4 ADC<\/li>\n<li class=\"toc-level-3\">5.1.4 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4<\/li>\n<li class=\"toc-level-4\">5.1.4.1 \uc5d4\ud3ec\ub974\ud22c\ub9d9 \ubca0\ub3c4\ud2f4<\/li>\n<li class=\"toc-level-4\">5.1.4.2 \uc0ac\uc2dc\ud22c\uc8fc\ub9d9 \uace0\ube44\ud14c\uce78<\/li>\n<li class=\"toc-level-4\">5.1.4.3 \ud30c\uc774\ud504\ub77c\uc778 ADC<\/li>\n<li class=\"toc-level-3\">5.1.5 \ubc29\uad11 \ub0b4 \uce58\ub8cc<\/li>\n<li class=\"toc-level-4\">5.1.5.1 BCG<\/li>\n<li class=\"toc-level-4\">5.1.5.2 \uc720\uc804\uc790\/\ubc14\uc774\ub7ec\uc2a4 \uce58\ub8cc<\/li>\n<li class=\"toc-level-4\">5.1.5.3 \ud654\ud559\uc628\uc5f4\uc694\ubc95<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uce58\ub8cc \ub77c\uc778\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 1\ucc28 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.2.2 \uc720\uc9c0 \/ \uacf5\uace0<\/li>\n<li class=\"toc-level-3\">5.2.3 2\ucc28 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.2.4 3\ucc28 \uce58\ub8cc \ubc0f \uadf8 \uc774\uc0c1<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc554 \ubcd1\uae30\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \ube44\uadfc\uce68\uc724\uc131 \ubc29\uad11\uc554 (NMIBC)<\/li>\n<li class=\"toc-level-3\">5.3.2 \uadfc\uce68\uc724\uc131 \ubc29\uad11\uc554 (MIBC)<\/li>\n<li class=\"toc-level-3\">5.3.3 \uc804\uc774\uc131 \uc694\ub85c\uc0c1\ud53c\uc554 (mUC)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \ubc14\uc774\uc624\ub9c8\ucee4 \uc0c1\ud0dc\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 FGFR2\/3 \ubcc0\ud615<\/li>\n<li class=\"toc-level-3\">5.4.2 PD-L1 \uace0\ubc1c\ud604<\/li>\n<li class=\"toc-level-3\">5.4.3 \ub125\ud2f4-4 \uace0\ubc1c\ud604<\/li>\n<li class=\"toc-level-3\">5.4.4 HER2 \uc591\uc131<\/li>\n<li class=\"toc-level-3\">5.4.5 \ubc14\uc774\uc624\ub9c8\ucee4 \ubbf8\uc120\ud0dd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \uc720\ud1b5 \ucc44\ub110\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \ubcd1\uc6d0 \uc57d\uad6d<\/li>\n<li class=\"toc-level-3\">5.5.2 \uc804\ubb38 \ud074\ub9ac\ub2c9<\/li>\n<li class=\"toc-level-3\">5.5.3 \uc628\ub77c\uc778 \uc57d\uad6d<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.6 \uc9c0\uc5ed\n<ul>\n<li class=\"toc-level-3\">5.6.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.6.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.6.1.3 \uba55\uc2dc\ucf54<\/li>\n<li class=\"toc-level-3\">5.6.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.6.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.6.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.6.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.6.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.6.2.6 \uae30\ud0c0 \uc720\ub7fd<\/li>\n<li class=\"toc-level-3\">5.6.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.6.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.6.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.6.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.6.3.6 \uae30\ud0c0 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-3\">5.6.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.6.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.6.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.6.4.3 \uae30\ud0c0 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-3\">5.6.5 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.6.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.6.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.6.5.3 \uae30\ud0c0 \ub0a8\ubbf8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4(\uc0ac\uc6a9 \uac00\ub2a5\ud55c \uacbd\uc6b0), \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 &amp; \uc11c\ube44\uc2a4, \ubc0f \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 Merck &amp; Co., Inc.<\/li>\n<li class=\"toc-level-3\">6.3.2 F. Hoffmann-La Roche AG<\/li>\n<li class=\"toc-level-3\">6.3.3 Bristol-Myers Squibb Company<\/li>\n<li class=\"toc-level-3\">6.3.4 AstraZeneca PLC<\/li>\n<li class=\"toc-level-3\">6.3.5 Novartis AG<\/li>\n<li class=\"toc-level-3\">6.3.6 GSK PLC<\/li>\n<li class=\"toc-level-3\">6.3.7 Sanofi SA<\/li>\n<li class=\"toc-level-3\">6.3.8 Eisai Co., Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.9 Astellas Pharma Inc.<\/li>\n<li class=\"toc-level-3\">6.3.10 UroGen Pharma Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.11 Pfizer Inc.<\/li>\n<li class=\"toc-level-3\">6.3.12 Seagen Inc.<\/li>\n<li class=\"toc-level-3\">6.3.13 Johnson &amp; Johnson (Janssen Biotech)<\/li>\n<li class=\"toc-level-3\">6.3.14 Gilead Sciences Inc.<\/li>\n<li class=\"toc-level-3\">6.3.15 ImmunityBio Inc.<\/li>\n<li class=\"toc-level-3\">6.3.16 CG Oncology Inc.<\/li>\n<li class=\"toc-level-3\">6.3.17 QED Therapeutics Inc.<\/li>\n<li class=\"toc-level-3\">6.3.18 BeiGene Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.19 Mirati Therapeutics Inc.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c &amp; \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ube44\ub1e8\uae30\uacc4\uc554 \uc57d\ubb3c \uc2dc\uc7a5 \uac1c\uc694: 2031\ub144\uae4c\uc9c0\uc758 \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc608\uce21<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \ube44\ub1e8\uae30\uacc4\uc554 \uc57d\ubb3c \uc2dc\uc7a5\uc758 \uc131\uc7a5 \ub3d9\ud5a5\uacfc \uc608\uce21(2026-2031)\uc744 \ub2e4\ub8e8\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc2dc\uc7a5\uc740 \uce58\ub8cc\ubc95(\ud654\ud559\uc694\ubc95, \uba74\uc5ed\uc694\ubc95 \ub4f1), \uce58\ub8cc \ub2e8\uacc4(1\ucc28, 2\ucc28 \ub4f1), \uc554 \ubcd1\uae30(\uc804\uc774\uc131 \uc694\ub85c\uc0c1\ud53c\uc554 \ub4f1), \ubc14\uc774\uc624\ub9c8\ucee4 \uc0c1\ud0dc(FGFR2\/3 \ubcc0\uc774 \ub4f1), \uc720\ud1b5 \ucc44\ub110(\ubcd1\uc6d0 \uc57d\uad6d \ub4f1) \ubc0f \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd \ub4f1)\ubcc4\ub85c \uc138\ubd84\ud654\ub418\uc5b4 \uc788\uc73c\uba70, \uc2dc\uc7a5 \uc608\uce21\uc740 \uac00\uce58(USD) \uae30\uc900\uc73c\ub85c \uc81c\uacf5\ub429\ub2c8\ub2e4.<\/p>\n<p># \uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc8fc\uc694 \uc218\uce58<\/p>\n<p>*   \uc5f0\uad6c \uae30\uac04: 2020 &#8211; 2031\ub144<br \/>\n*   2026\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 44.7\uc5b5 \ub2ec\ub7ec<br \/>\n*   2031\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 77.5\uc5b5 \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026 &#8211; 2031): \uc5f0\ud3c9\uade0 11.66% (CAGR)<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04<br \/>\n*   \uc8fc\uc694 \uae30\uc5c5: Merck &#038; Co. Inc., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, AstraZeneca PLC<\/p>\n<p># \uc2dc\uc7a5 \ubd84\uc11d<\/p>\n<p>Mordor Intelligence\uc758 \ubd84\uc11d\uc5d0 \ub530\ub974\uba74, \ube44\ub1e8\uae30\uacc4\uc554 \uc57d\ubb3c \uc2dc\uc7a5\uc740 2025\ub144 40\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 44.7\uc5b5 \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2031\ub144\uc5d0\ub294 77.5\uc5b5 \ub2ec\ub7ec\uc5d0 \ub3c4\ub2ec\ud558\uc5ec 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 11.66%\uc758 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \uc9c8\ubcd1 \ubc1c\uc0dd\ub960 \uc99d\uac00, \uba74\uc5ed\ud56d\uc554\uc81c(IO)\uc758 \ube60\ub978 \ub3c4\uc785, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778, \uc815\ubc00 \uc758\ud559\uc5d0 \ub300\ud55c \uc9c0\uc18d\uc801\uc778 \ud22c\uc790 \ud655\ub300\uc5d0 \uae30\uc778\ud569\ub2c8\ub2e4.<\/p>\n<p>ADC\uc640 \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\ub97c \uacb0\ud569\ud55c \ubcd1\uc6a9 \uc694\ubc95\uc740 1\ucc28 \uce58\ub8cc\uc758 \uc0c8\ub85c\uc6b4 \ud45c\uc900\uc744 \uc81c\uc2dc\ud558\uace0 \uc788\uc73c\uba70, \ubc14\uc774\uc624\ub9c8\ucee4 \uae30\ubc18 \ud504\ub85c\ud1a0\ucf5c\uc740 \uce58\ub8cc \uc815\ud655\ub3c4\ub97c \ub192\uc774\uace0 \uc0dd\uc874\uc728\uc744 \uc5f0\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubd81\ubbf8\ub294 \ucd08\uae30 \uae30\uc220 \ucc44\ud0dd\uacfc \uad00\ub300\ud55c \ubcf4\ud5d8 \ubcf4\uc7a5\uc73c\ub85c \uc2dc\uc7a5\uc744 \uc120\ub3c4\ud558\uace0 \uc788\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \ud65c\ubc1c\ud55c \uac80\uc9c4 \uc774\ub2c8\uc154\ud2f0\ube0c\uc640 \ud655\uc7a5\ub418\ub294 \uc885\uc591\ud559 \uc778\ud504\ub77c\ub97c \ud1b5\ud574 \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5\uc744 \ubcf4\uc774\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\uc18d\uc801\uc778 BCG(Bacille Calmette-Gu\u00e9rin) \ubd80\uc871\uc740 \ucc28\uc138\ub300 \ubc29\uad11 \ub0b4 \uc57d\ubb3c \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uae30\ud68c\ub97c \ud655\ub300\ud558\uc9c0\ub9cc, \ub3d9\uc2dc\uc5d0 \uacf5\uae09\ub9dd \ucde8\uc57d\uc131\uc744 \ub4dc\ub7ec\ub0b4\uace0 \uc788\uc5b4 \uc774\ud574\uad00\uacc4\uc790\ub4e4\uc758 \ud574\uacb0\uc774 \ud544\uc694\ud569\ub2c8\ub2e4.<\/p>\n<p># \uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>*   \uce58\ub8cc\ubc95\ubcc4: 2025\ub144 \uba74\uc5ed\uc694\ubc95\uc774 45.02%\uc758 \uc2dc\uc7a5 \uc810\uc720\uc728\ub85c \uc120\ub450\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, ADC\ub294 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 18.21%\ub85c \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uce58\ub8cc \ub2e8\uacc4\ubcc4: 2025\ub144 1\ucc28 \uce58\ub8cc \uc635\uc158\uc774 56.01%\uc758 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \uae30\ub85d\ud588\uc73c\uba70, \uc720\uc9c0\/\uac15\ud654 \uce58\ub8cc\ub294 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 12.66%\ub85c \uc99d\uac00\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc554 \ubcd1\uae30\ubcc4: 2025\ub144 \ube44\uadfc\uce68\uc2b5\uc131 \ubc29\uad11\uc554\uc774 47.21%\uc758 \uc810\uc720\uc728\uc744 \ubcf4\uc600\uc73c\ub098, \uc804\uc774\uc131 \uc9c8\ud658\uc740 \uac19\uc740 \uae30\uac04 \ub3d9\uc548 \uc5f0\ud3c9\uade0 13.62%\ub85c \uc0c1\uc2b9\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ubc14\uc774\uc624\ub9c8\ucee4 \uc0c1\ud0dc\ubcc4: 2025\ub144 \ubc14\uc774\uc624\ub9c8\ucee4 \ubbf8\uc120\ud0dd \ucf54\ud638\ud2b8\uac00 61.68%\uc758 \ub9e4\ucd9c\uc744 \ucc28\uc9c0\ud588\uc73c\uba70, FGFR2\/3 \ubcc0\uc774 \ud658\uc790\uad70\uc740 \uc5f0\ud3c9\uade0 19.12%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \ud2c8\uc0c8 \uc2dc\uc7a5\uc744 \uad6c\uc131\ud569\ub2c8\ub2e4.<br \/>\n*   \uc720\ud1b5 \ucc44\ub110\ubcc4: 2025\ub144 \ubcd1\uc6d0 \uc57d\uad6d\uc774 67.44%\uc758 \uc810\uc720\uc728\uc744 \uae30\ub85d\ud588\uc73c\uba70, \uc628\ub77c\uc778 \uc57d\uad6d\uc740 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 17.98%\ub85c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\uac00 42.88%\uc758 \uc810\uc720\uc728\uc744 \ucc28\uc9c0\ud588\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc740 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 12.11%\uc758 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p># \uae00\ub85c\ubc8c \ube44\ub1e8\uae30\uacc4\uc554 \uc57d\ubb3c \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30<\/p>\n<p>\uc131\uc7a5 \ub3d9\uc778 (Drivers)<\/p>\n<p>*   \uc804 \uc138\uacc4 \ube44\ub1e8\uae30\uacc4\uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00: \uace0\uc18c\ub4dd \uad6d\uac00\uc5d0\uc11c \ubc29\uad11\uc554 \uc9c4\ub2e8\uc774 \uc0c1\uc704 6\ub300 \uc545\uc131 \uc885\uc591\uc5d0 \uc18d\ud558\uba70, \uc2e0\ud765 \uacbd\uc81c\uad6d\uc5d0\uc11c\ub3c4 \uac00\uc18d\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud658\uacbd \ubc1c\uc554 \ubb3c\uc9c8, \uace0\ub839\ud654 \uc778\uad6c, \ubc29\uad11\uacbd \uac80\uc9c4 \uc811\uadfc\uc131 \ud655\ub300 \ub4f1\uc774 \uc2e0\uaddc \uce58\ub8cc\uc81c \ub300\uc0c1 \ud658\uc790\uad70\uc744 \ub298\ub9ac\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\uc758 1\ucc28 \uce58\ub8cc \ud45c\uc900 \ucc44\ud0dd: \ud3a8\ube0c\ub864\ub9ac\uc8fc\ub9d9(pembrolizumab) \ubc0f \ub354\ubc1c\ub8e8\ub9d9(durvalumab)\uacfc \uac19\uc740 \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\uac00 2024\ub144 \uc5ec\ub7ec \uc9c8\ubcd1 \ub2e8\uacc4\uc5d0\uc11c \uad11\ubc94\uc704\ud55c 1\ucc28 \uce58\ub8cc \uc2b9\uc778\uc744 \ubc1b\uc73c\uba70 \uc2dc\uc2a4\ud50c\ub77c\ud2f4 \uae30\ubc18 \ud654\ud559\uc694\ubc95\uc744 \ub300\uccb4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc5d4\ud3ec\ub974\ud22c\ub9d9 \ubca0\ub3c4\ud2f4(enfortumab vedotin)\uacfc \ud3a8\ube0c\ub864\ub9ac\uc8fc\ub9d9 \ubcd1\uc6a9 \uc694\ubc95\uacfc \uac19\uc740 \ud504\ub85c\ud1a0\ucf5c\uc740 \ucd5c\uc801\uc758 \uce58\ub8cc\ubc95\uc744 \uc7ac\uc815\uc758\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778: \ubbf8\uad6d \ubc0f \uc720\ub7fd \uaddc\uc81c \ub2f9\uad6d\uc740 \ud601\uc2e0 \uce58\ub8cc\uc81c \ubc0f \uc2e0\uc18d \uc2b9\uc778 \uacbd\ub85c\ub97c \ud1b5\ud574 ADC \uc2ec\uc0ac\ub97c \uac00\uc18d\ud654\ud558\uc5ec \uac1c\ubc1c \uae30\uac04\uc744 \ub2e8\ucd95\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub3d9\ubc18 \uc9c4\ub2e8(CDx) \uc2b9\uc778\ub3c4 \uc0c1\uc5c5\ud654\ub97c \uc6d0\ud65c\ud558\uac8c \ud569\ub2c8\ub2e4.<br \/>\n*   \ub300\ud615 \uc81c\uc57d\uc0ac\uc758 \ud30c\ud2b8\ub108\uc2ed\uc744 \ud1b5\ud55c FGFR \uc5b5\uc81c\uc81c \ucd9c\uc2dc \uac00\uc18d\ud654: \ubc14\uc774\uc624\ud14d\uc758 \ubc1c\uacac \ud50c\ub7ab\ud3fc\uacfc \ub300\ud615 \uc81c\uc57d\uc0ac\uc758 \uaddc\ubaa8\uac00 \uacb0\ud569\ub41c \ud611\ub825\uc740 \uc5d0\ub974\ub2e4\ud53c\ud2f0\ub2d9(erdafitinib)\uacfc \uac19\uc740 FGFR \ud45c\uc801 \uc57d\ubb3c\uc758 \uc2dc\uc7a5 \ucd9c\uc2dc \uae30\uac04\uc744 \ub2e8\ucd95\ud569\ub2c8\ub2e4. \uacf5\ub3d9 \uac1c\ubc1c \uacc4\uc57d\uc740 \uc8fc\uc694 \uc784\uc0c1 \uc2dc\ud5d8 \ubc0f \uc0c1\uc5c5\ud654\uc5d0 \ud544\uc694\ud55c \uc790\uc6d0\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<br \/>\n*   AI \uae30\ubc18 \uc18c\ubcc0 \ubc14\uc774\uc624\ub9c8\ucee4 \uc9c4\ub2e8\uc73c\ub85c \uce58\ub8cc \uac00\ub2a5 \ud658\uc790\uad70 \ud655\ub300: AI \uae30\ubc18 \uc9c4\ub2e8 \uae30\uc220\uc740 \uce58\ub8cc \uac00\ub2a5\ud55c \ud658\uc790 \ud480\uc744 \ud655\ub300\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   ADC + IO \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \uba54\ub514\ucf00\uc5b4 \ubc0f \ubbfc\uac04 \ubcf4\ud5d8\uc0ac\uc758 \ubcf4\uc7a5 \ud655\ub300: \ubd81\ubbf8\ub97c \uc911\uc2ec\uc73c\ub85c ADC\uc640 IO \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \ubcf4\ud5d8 \ubcf4\uc7a5\uc774 \ud655\ub300\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc81c\uc57d \uc694\uc778 (Restraints)<\/p>\n<p>*   \uba74\uc5ed\uc694\ubc95 \ubc0f ADC\uc758 \ub192\uc740 \ube44\uc6a9: \uc120\uc9c4\uad6d\uc5d0\uc11c \ubcd1\uc6a9 \uc694\ubc95\uc758 \uc5f0\uac04 \uce58\ub8cc \ube44\uc6a9\uc740 \ud658\uc790\ub2f9 20\ub9cc \ub2ec\ub7ec\ub97c \ucd08\uacfc\ud558\uc5ec \ubcf4\ud5d8 \uc7ac\uc815\uc5d0 \ubd80\ub2f4\uc744 \uc8fc\uace0 \uc0ac\uc804 \uc2b9\uc778 \uc808\ucc28\ub97c \uac15\ud654\ud569\ub2c8\ub2e4. \uc2e0\ud765 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \uc81c\ud55c\ub41c \ubcf4\ud5d8 \ubcf4\uc7a5\uc73c\ub85c \uc778\ud574 \ucc44\ud0dd\uc774 \uc5b4\ub835\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uba74\uc5ed \uad00\ub828 \uc774\uc0c1 \ubc18\uc751(irAE)\uc73c\ub85c \uc778\ud55c \uc7a5\uae30 \uc21c\uc751\ub3c4 \uc800\ud574: \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c\ub294 \uce58\ub8cc \ud658\uc790\uc758 \ucd5c\ub300 20%\uc5d0\uc11c \uce58\ub8cc \uc911\ub2e8\uc744 \ucd08\ub798\ud560 \uc218 \uc788\ub294 \uc790\uac00\uba74\uc5ed \ub3c5\uc131\uc744 \uc720\ubc1c\ud558\uc5ec \ub204\uc801 \uce58\ub8cc \ub178\ucd9c \ubc0f \ub9e4\ucd9c \uc2e4\ud604\uc744 \uac10\uc18c\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uc804 \uc138\uacc4 BCG \uc81c\uc870 \ubd80\uc871\uc73c\ub85c NMIBC \uce58\ub8cc \uc9c0\uc5f0: \uc9c0\uc18d\uc801\uc778 BCG \uacf5\uae09 \ubd80\uc871\uc740 \ube44\uadfc\uce68\uc2b5\uc131 \ubc29\uad11\uc554(NMIBC) \uce58\ub8cc\uc5d0 \ucc28\uc9c8\uc744 \ube5a\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc2e0\ud765 \uc2dc\uc7a5\uc5d0\uc11c \ub3d9\ubc18 \uc9c4\ub2e8 \ud14c\uc2a4\ud2b8 \uc811\uadfc\uc131 \uc81c\ud55c: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub77c\ud2f4 \uc544\uba54\ub9ac\uce74 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \ub3d9\ubc18 \uc9c4\ub2e8 \ud14c\uc2a4\ud2b8\uc5d0 \ub300\ud55c \uc811\uadfc\uc131\uc774 \uc81c\ud55c\uc801\uc785\ub2c8\ub2e4.<\/p>\n<p># \uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>\uce58\ub8cc\ubc95\ubcc4 (By Treatment Class)<br \/>\nADC\ub294 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 18.21%\ub85c \uac00\uc7a5 \ube60\ub978 \ub9e4\ucd9c \uc131\uc7a5\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc5d4\ud3ec\ub974\ud22c\ub9d9 \ubca0\ub3c4\ud2f4(enfortumab vedotin)\uc758 EV-302 \ub370\uc774\ud130\uac00 \ubbf8\uce58\ub8cc \uc804\uc774\uc131 \uc9c8\ud658\uc5d0\uc11c \uc0dd\uc874\uc728 \uae30\uc900\uc744 \uc7ac\uc124\uc815\ud558\uba74\uc11c \uc774\ub7ec\ud55c \uc131\uc7a5\uc744 \uc8fc\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uba74\uc5ed\uc694\ubc95\uc740 2025\ub144 \ube44\ub1e8\uae30\uacc4\uc554 \uc57d\ubb3c \uc2dc\uc7a5\uc758 45.02%\ub97c \ucc28\uc9c0\ud558\uba70 \uc9c0\ubc30\uc801\uc778 \uc704\uce58\ub97c \uc720\uc9c0\ud588\uc9c0\ub9cc, \ub2e8\uc77c \uc81c\uc81c \ubc18\uc751\ub960\uc758 \uc815\uccb4\ub85c \uc778\ud574 ADC\uc640 \uacb0\ud569\ub41c \uc2dc\ub108\uc9c0 \ud6a8\uacfc\ub97c \ub0b4\ub294 \ubcd1\uc6a9 \uc694\ubc95\uc774 \uc8fc\ubaa9\ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubc31\uae08 \uae30\ubc18 \ud654\ud559\uc694\ubc95\uc740 \uc2dc\uc2a4\ud50c\ub77c\ud2f4 \uc801\uaca9 \ud658\uc790\uc5d0\uac8c \uc5ec\uc804\ud788 \uc911\uc694\ud558\uba70, \uc720\uc804\uc790 \uce58\ub8cc \ubc0f \ud654\ud559\uc628\uc5f4\uc694\ubc95\uc740 BCG \ubd80\uc871 \uc0c1\ud669\uc5d0\uc11c \ubc29\uad11 \ub0b4 \uce58\ub8cc\uc758 \ud2c8\uc0c8\uc2dc\uc7a5\uc744 \ucc44\uc6b0\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud30c\uc774\ud504\ub77c\uc778\uc758 \ud3ed\ub113\uc740 ADC \uac1c\ubc1c\uc740 \uc9c0\uc18d\uc801\uc778 \uc131\uc7a5\uc744 \ubcf4\uc7a5\ud558\uba70, \uc0c8\ub85c\uc6b4 \ud56d\uc6d0, \ucd5c\uc801\ud654\ub41c \ub9c1\ucee4, \ud5a5\uc0c1\ub41c \uc57d\ubb3c-\ud56d\uccb4 \ube44\uc728\uc744 \ubaa9\ud45c\ub85c \ud558\ub294 \ucc28\uc138\ub300 ADC\uac00 \uc2dc\uc7a5 \uaddc\ubaa8\ub97c \ud655\ub300\ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p>\uce58\ub8cc \ub2e8\uacc4\ubcc4 (By Line of Therapy)<br \/>\n1\ucc28 \uce58\ub8cc \uc694\ubc95\uc740 2025\ub144 \ub9e4\ucd9c\uc758 56.01%\ub97c \ucc28\uc9c0\ud558\uba70 \ucd08\uae30 \uce58\ub8cc \uc120\ud0dd\uc758 \uacbd\uc81c\uc801 \uc911\uc694\uc131\uc744 \uac15\uc870\ud569\ub2c8\ub2e4. \uc544\ubca8\ub8e8\ub9d9(avelumab)\uc774 \uc8fc\ub3c4\ud558\ub294 \uc720\uc9c0 \uc694\ubc95\uc740 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 12.66%\uc758 \uc131\uc7a5\ub960\uc744 \ubcf4\uc774\uba70, \uc9c8\ubcd1 \uc9c4\ud589 \uc5c6\ub294 \uc0dd\uc874 \uae30\uac04 \uc5f0\uc7a5\uc774\ub77c\ub294 \uac00\uce58\ub97c \uc81c\uacf5\ud558\uc5ec \uc784\uc0c1\uc758\uc640 \ubcf4\ud5d8\uc0ac \ubaa8\ub450\uc5d0\uac8c \uae0d\uc815\uc801\uc778 \ubc18\uc751\uc744 \uc5bb\uace0 \uc788\uc2b5\ub2c8\ub2e4. 2\ucc28 \uce58\ub8cc \ub2e8\uacc4\ub294 \ub0b4\uc131\uc774 \ubc1c\uc0dd\ud558\ub294 \uc911\uc694\ud55c \uc601\uc5ed\uc73c\ub85c, ADC \ubc0f \ud45c\uc801 \uc5b5\uc81c\uc81c\uac00 \uae30\uc874 \ud654\ud559\uc694\ubc95\ubcf4\ub2e4 \uc6b0\uc218\uc131\uc744 \uc785\uc99d\ud560 \uae30\ud68c\ub97c \uc81c\uacf5\ud569\ub2c8\ub2e4. 3\ucc28 \ubc0f \uad6c\uc81c \uce58\ub8cc \ud658\uacbd\uc740 \uaddc\ubaa8\ub294 \uc791\uc9c0\ub9cc, \uc885\uc591 \uc6a9\ud574 \ubc14\uc774\ub7ec\uc2a4\uc640 \uac19\uc740 \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\ubc95\uc774 \uc810\uc9c4\uc801\uc778 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \ud655\ubcf4\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc554 \ubcd1\uae30\ubcc4 (By Cancer Stage)<br \/>\n\ube44\uadfc\uce68\uc2b5\uc131 \ubc29\uad11\uc554(NMIBC)\uc740 \ub192\uc740 \ubc1c\ubcd1\ub960\uacfc \uae30\uc874 \ubc29\uad11 \ub0b4 \uce58\ub8cc \ud504\ub85c\ud1a0\ucf5c \ub355\ubd84\uc5d0 2025\ub144 \ub9e4\ucd9c\uc758 47.21%\ub97c \ucc28\uc9c0\ud558\uba70 \uc9c0\ubc30\uc801\uc774\uc5c8\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc804\uc774\uc131 \uc694\ub85c\uc0c1\ud53c\uc554\uc740 \ubbf8\ucda9\uc871 \uc218\uc694\uac00 \ud070 \uc0c8\ub85c\uc6b4 \uc804\uc2e0 \uce58\ub8cc\uc81c \uac1c\ubc1c\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 13.62%\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \ub098\ub3c4\ud30c\ub77c\uc9c4 \ud53c\ub77c\ub370\ub178\ubca1(nadofaragene firadenovec) \ubc0f \ub178\uac00\ud39c\ub370\ud0a8 \uc54c\ud30c-\uc778\ubc14\ud0a4\uc149\ud2b8(nogapendekin alfa-inbakicept)\uc5d0 \ub300\ud55c FDA \uc2b9\uc778\uc740 BCG \ubd88\uc751\uc131 \ud658\uc790\uc5d0\uac8c \ubc29\uad11 \ubcf4\uc874 \uc635\uc158\uc744\uc81c\uacf5\ud569\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc0c8\ub85c\uc6b4 \uce58\ub8cc\ubc95\uc740 \uae30\uc874\uc758 \uce68\uc2b5\uc801\uc778 \uce58\ub8cc\ubc95\uc5d0 \ub300\ud55c \ub300\uc548\uc744 \uc81c\uc2dc\ud558\uba70 \ud658\uc790\uc758 \uc0b6\uc758 \uc9c8\uc744 \ud5a5\uc0c1\uc2dc\ud0a4\ub294 \ub370 \uae30\uc5ec\ud560 \uac83\uc73c\ub85c \uae30\ub300\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc774 \ubcf4\uace0\uc11c\ub294 \uc694\ub85c\uc0c1\ud53c\uc554(Urothelial Cancer) \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \uc694\ub85c\uc0c1\ud53c\uc554\uc740 \ubc29\uad11, \uc694\ub3c4, \uc694\uad00 \ubc0f \uc2e0\uc6b0 \ub0b4\ubcbd\uc5d0 \ubc1c\uc0dd\ud558\ub294 \uc554\uc73c\ub85c, \ubcf8 \ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5 \uc815\uc758, \uc5f0\uad6c \ubc94\uc704 \ubc0f \ubc29\ubc95\ub860\uc744 \ud3ec\ud568\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ub3d9\uc778 \ubc0f \uc81c\uc57d:<br \/>\n\uc8fc\uc694 \uc2dc\uc7a5 \ub3d9\uc778\uc73c\ub85c\ub294 \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uc99d\uac00\ud558\ub294 \uc694\ub85c\uc0c1\ud53c\uc554 \ubc1c\ubcd1\ub960, \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c(Immune-Checkpoint Inhibitors)\uc758 1\ucc28 \uce58\ub8cc\uc81c \ud45c\uc900 \ucc44\ud0dd \uc99d\uac00, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\uc5d0 \ub300\ud55c \uaddc\uc81c \uc2e0\uc18d \uc2b9\uc778, \ub300\ud615 \uc81c\uc57d\uc0ac\ub4e4\uc758 \ud30c\ud2b8\ub108\uc2ed\uc744 \ud1b5\ud55c FGFR \uc5b5\uc81c\uc81c \ucd9c\uc2dc \uac00\uc18d\ud654, AI \uae30\ubc18 \uc18c\ubcc0 \ubc14\uc774\uc624\ub9c8\ucee4 \uc9c4\ub2e8\uc744 \ud1b5\ud55c \uce58\ub8cc \uac00\ub2a5 \ud658\uc790\uad70 \ud655\ub300, \uadf8\ub9ac\uace0 ADC \ubc0f \uba74\uc5ed\ud56d\uc554\uc81c(IO) \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \uba54\ub514\ucf00\uc5b4 \ubc0f \ubbfc\uac04 \ubcf4\ud5d8\uc0ac\uc758 \ubcf4\uc0c1 \ud655\ub300 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uba74\uc5ed\ud56d\uc554\uc81c \ubc0f ADCs\uc758 \ub192\uc740 \ube44\uc6a9, \uba74\uc5ed \uad00\ub828 \uc774\uc0c1 \ubc18\uc751\uc73c\ub85c \uc778\ud55c \uc7a5\uae30 \ubcf5\uc57d \uc21c\uc751\ub3c4 \uc800\ud558, BCG \uc81c\uc870 \ubd80\uc871\uc73c\ub85c \uc778\ud55c \ube44\uadfc\uce68\uc724\uc131 \ubc29\uad11\uc554(NMIBC) \uce58\ub8cc \uc9c0\uc5f0, \uadf8\ub9ac\uace0 \uc2e0\ud765 \uc2dc\uc7a5\uc5d0\uc11c\uc758 \ub3d9\ubc18 \uc9c4\ub2e8(Companion-Diagnostic) \ud14c\uc2a4\ud2b8 \uc811\uadfc \uc81c\ud55c \ub4f1\uc774 \uc9c0\uc801\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc138\ubd84\ud654:<br \/>\n\ubcf8 \ubcf4\uace0\uc11c\ub294 \uce58\ub8cc\uc81c \uc885\ub958(\ud654\ud559\uc694\ubc95, \uba74\uc5ed\uc694\ubc95, \ud45c\uc801\uce58\ub8cc\uc81c, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4, \ubc29\uad11 \ub0b4 \uce58\ub8cc), \uce58\ub8cc \ub2e8\uacc4(1\ucc28, \uc720\uc9c0\/\uac15\ud654, 2\ucc28, 3\ucc28 \uc774\uc0c1), \uc554 \ubcd1\uae30(\ube44\uadfc\uce68\uc724\uc131 \ubc29\uad11\uc554, \uadfc\uce68\uc724\uc131 \ubc29\uad11\uc554, \uc804\uc774\uc131 \uc694\ub85c\uc0c1\ud53c\uc554), \ubc14\uc774\uc624\ub9c8\ucee4 \uc0c1\ud0dc(FGFR2\/3 \ubcc0\uc774, PD-L1 \uace0\ubc1c\ud604, Nectin-4 \uace0\ubc1c\ud604, HER2 \uc591\uc131, \ubc14\uc774\uc624\ub9c8\ucee4 \ubbf8\uc120\ud0dd), \uc720\ud1b5 \ucc44\ub110(\ubcd1\uc6d0 \uc57d\uad6d, \uc804\ubb38 \ud074\ub9ac\ub2c9, \uc628\ub77c\uc778 \uc57d\uad6d) \ubc0f \uc9c0\uc5ed\ubcc4(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8)\ub85c \uc2dc\uc7a5\uc744 \uc138\ubd84\ud654\ud558\uc5ec \ubd84\uc11d\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc804\ub9dd:<br \/>\n\uc694\ub85c\uc0c1\ud53c\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2026\ub144 \uae30\uc900 44\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\ub85c \ud3c9\uac00\ub418\uba70, \uba74\uc5ed\ud56d\uc554\uc81c \ubc0f ADC \ubcd1\uc6a9 \uc694\ubc95\uc758 \ube60\ub978 \ucc44\ud0dd\uc5d0 \ud798\uc785\uc5b4 \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\ub294 \uc5d4\ud3ec\ub974\ud22c\ub9d9 \ubca0\ub3c4\ud2f4(enfortumab vedotin) \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \uc758\ud574 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 18.21%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uce58\ub8cc\uc81c \ud074\ub798\uc2a4\ub85c \uc608\uce21\ub429\ub2c8\ub2e4. \ud604\uc7ac \ubd81\ubbf8 \uc9c0\uc5ed\uc774 42.88%\uc758 \uc2dc\uc7a5 \uc810\uc720\uc728\ub85c \uac00\uc7a5 \ud070 \ube44\uc911\uc744 \ucc28\uc9c0\ud558\uace0 \uc788\uc73c\uba70, \uad00\ub300\ud55c \ubcf4\ud5d8 \ubcf4\uc0c1\uacfc \ud601\uc2e0 \uce58\ub8cc\uc81c\uc758 \uc870\uae30 \ub3c4\uc785\uc774 \uc8fc\ub41c \uc694\uc778\uc785\ub2c8\ub2e4. \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uc554 \uac80\uc9c4 \ud655\ub300, \uc778\ud504\ub77c \uac1c\uc120, \ubcf4\ud5d8 \uc801\uc6a9 \ud655\ub300\ub85c \uc778\ud574 2031\ub144\uae4c\uc9c0 12.11%\uc758 CAGR\uc744 \uae30\ub85d\ud558\uba70 \ub2e4\ub978 \uc9c0\uc5ed\ubcf4\ub2e4 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubc0f \uc8fc\uc694 \uae30\uc5c5:<br \/>\n\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc740 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d \ubc0f \uc8fc\uc694 \uae30\uc5c5 \ud504\ub85c\ud544\uc744 \ud3ec\ud568\ud569\ub2c8\ub2e4. \uc8fc\uc694 \uae30\uc5c5\uc73c\ub85c\ub294 Merck &#038; Co., F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca, Novartis, GSK, Sanofi, Eisai, Astellas Pharma, Pfizer, Seagen, Johnson &#038; Johnson, Gilead Sciences \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd:<br \/>\n\ubcf4\uace0\uc11c\ub294 \ub610\ud55c \uc2dc\uc7a5 \uae30\ud68c\uc640 \ubbf8\ub798 \uc804\ub9dd, \ubbf8\ucda9\uc871 \uc218\uc694 \ud3c9\uac00\ub97c \ub2e4\ub8e8\uba70, \ud5a5\ud6c4 \uc2dc\uc7a5\uc758 \ubc1c\uc804 \ubc29\ud5a5\uc744 \uc81c\uc2dc\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-43559","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/43559"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=43559"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/43559\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=43559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=43559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=43559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}